View Post

HER2CLIMB: Tucatinib Boosts OS in Breast Cancer Patients With Brain Mets

In In The News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com — Updated results show 9-month survival benefit in those with active or untreated brain metastases At the virtual San Antonio Breast Cancer Symposium, researchers presented new data from an exploratory analyses from the pivotal HER2CLIMB trial. After an additional 15.6 months of follow-up, the overall survival (OS) benefit when tucatinib (Tukysa) was added to trastuzumab …

View Post

Can CDK4/6 Inhibitors Be Optimized for Breast Cancer?

In Clinical Studies News by Barbara Jacoby

By; Lynne Lederman, PhD From: targetedonc.com Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib. Can treatment with inhibitors of cyclindependent kinases 4 and 6 (CDK4/6is) be optimized for patients with breast cancer? This remains an …